Dendritic Cell-Based Immunotherapy for Prostate Cancer

Table 1

PCa-associated antigen-derived CD8⁺ T-cell epitopes used for DC-based immunotherapy.

Antigen	HLA restriction element	Peptide position	Amino acid sequence	References
Prostate-specific antigen (PSA)	HLA-A2	146–154	KLQCVDLHV	[23, 24]
		141–150	FLTPKKLQCV	[25, 26]
		154–163	VISNDVCAQV	[25–27]
Prostate-specific membrane antigen (PSMA)	HLA-A2	4–12	LLHETDSAV	[28, 29]
		711–719	ALFDIESKV	[29]
Prostatic acid phosphatase (PAP)	HLA-A2	299–307	ALDVYNGLL	[30]
Prostate stem cell antigen (PSCA)	HLA-A2	14–22	ALQPGTALL	[31, 32]
Prostein	HLA-A2	31–39	CLAAGITYV	[33]
Transient receptor potential-p8 (Trp-p8)	HLA-A2	187–195	GLMKYIGEV	[34]
Human telomerase reverse transcriptase (hTERT)	HLA-A2	540–548	ILAKFLHWL	[35, 36]
Survivin	HLA-A2	95–104	ELTLGEFLKL	[37, 38]